The global market for Patient-derived Xenograft (PDX) Models was valued at US$ 388 million in the year 2024 and is projected to reach a revised size of US$ 683 million by 2031, growing at a CAGR of 8.5% during the forecast period.
Global top 5 manufacturers of patient-derived xenograft (PDX) models occupied for a share nearly 45 percent, key players are Crown Bioscience, Champions Oncology, Wuxi Apptec, EPO Berlin-Buch, and Oncodesign, etc. Geographically speaking, Asia Pacific holds the most of global market share, about 35%. North America holds about 30% of share, while Europe followed by nearly 20%. In terms of type, mouse model accounted for nearly 75%, and rat model accounted for a share of 25%,The application of patient-derived xenograft (PDX) models includes preclinical drug development and biomarker analysis. Preclinical drug development shares over 75%, while biomarker analysis shares about 20%.
This report aims to provide a comprehensive presentation of the global market for Patient-derived Xenograft (PDX) Models, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Patient-derived Xenograft (PDX) Models.
The Patient-derived Xenograft (PDX) Models market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Patient-derived Xenograft (PDX) Models market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Patient-derived Xenograft (PDX) Models companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Crown Bioscience
Champions Oncology
Wuxi Apptec
The Jackson Laboratory
EPO Berlin-Buch
Oncodesign
Xentech
Envigo
Charles River Laboratories
Pharmatest Services
Urosphere
MEDICILON
Horizon Discovery
Shanghai Model Organisms Center
GemPharmatech
LIDE Biotech
Segment by Type
Mouse Model
Rat Model
Segment by Application
Preclinical Drug development
Biomarker Analysis
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Patient-derived Xenograft (PDX) Models company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Patient-derived Xenograft (PDX) Models Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Mouse Model
1.2.3 Rat Model
1.3 Market by Application
1.3.1 Global Patient-derived Xenograft (PDX) Models Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Preclinical Drug development
1.3.3 Biomarker Analysis
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Patient-derived Xenograft (PDX) Models Market Perspective (2020-2031)
2.2 Global Patient-derived Xenograft (PDX) Models Growth Trends by Region
2.2.1 Global Patient-derived Xenograft (PDX) Models Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Patient-derived Xenograft (PDX) Models Historic Market Size by Region (2020-2025)
2.2.3 Patient-derived Xenograft (PDX) Models Forecasted Market Size by Region (2026-2031)
2.3 Patient-derived Xenograft (PDX) Models Market Dynamics
2.3.1 Patient-derived Xenograft (PDX) Models Industry Trends
2.3.2 Patient-derived Xenograft (PDX) Models Market Drivers
2.3.3 Patient-derived Xenograft (PDX) Models Market Challenges
2.3.4 Patient-derived Xenograft (PDX) Models Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Patient-derived Xenograft (PDX) Models Players by Revenue
3.1.1 Global Top Patient-derived Xenograft (PDX) Models Players by Revenue (2020-2025)
3.1.2 Global Patient-derived Xenograft (PDX) Models Revenue Market Share by Players (2020-2025)
3.2 Global Patient-derived Xenograft (PDX) Models Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Patient-derived Xenograft (PDX) Models Revenue
3.4 Global Patient-derived Xenograft (PDX) Models Market Concentration Ratio
3.4.1 Global Patient-derived Xenograft (PDX) Models Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Patient-derived Xenograft (PDX) Models Revenue in 2024
3.5 Global Key Players of Patient-derived Xenograft (PDX) Models Head office and Area Served
3.6 Global Key Players of Patient-derived Xenograft (PDX) Models, Product and Application
3.7 Global Key Players of Patient-derived Xenograft (PDX) Models, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Patient-derived Xenograft (PDX) Models Breakdown Data by Type
4.1 Global Patient-derived Xenograft (PDX) Models Historic Market Size by Type (2020-2025)
4.2 Global Patient-derived Xenograft (PDX) Models Forecasted Market Size by Type (2026-2031)
5 Patient-derived Xenograft (PDX) Models Breakdown Data by Application
5.1 Global Patient-derived Xenograft (PDX) Models Historic Market Size by Application (2020-2025)
5.2 Global Patient-derived Xenograft (PDX) Models Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Patient-derived Xenograft (PDX) Models Market Size (2020-2031)
6.2 North America Patient-derived Xenograft (PDX) Models Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Patient-derived Xenograft (PDX) Models Market Size by Country (2020-2025)
6.4 North America Patient-derived Xenograft (PDX) Models Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Patient-derived Xenograft (PDX) Models Market Size (2020-2031)
7.2 Europe Patient-derived Xenograft (PDX) Models Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Patient-derived Xenograft (PDX) Models Market Size by Country (2020-2025)
7.4 Europe Patient-derived Xenograft (PDX) Models Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Patient-derived Xenograft (PDX) Models Market Size (2020-2031)
8.2 Asia-Pacific Patient-derived Xenograft (PDX) Models Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Patient-derived Xenograft (PDX) Models Market Size by Region (2020-2025)
8.4 Asia-Pacific Patient-derived Xenograft (PDX) Models Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Patient-derived Xenograft (PDX) Models Market Size (2020-2031)
9.2 Latin America Patient-derived Xenograft (PDX) Models Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Patient-derived Xenograft (PDX) Models Market Size by Country (2020-2025)
9.4 Latin America Patient-derived Xenograft (PDX) Models Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Patient-derived Xenograft (PDX) Models Market Size (2020-2031)
10.2 Middle East & Africa Patient-derived Xenograft (PDX) Models Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Patient-derived Xenograft (PDX) Models Market Size by Country (2020-2025)
10.4 Middle East & Africa Patient-derived Xenograft (PDX) Models Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Crown Bioscience
11.1.1 Crown Bioscience Company Details
11.1.2 Crown Bioscience Business Overview
11.1.3 Crown Bioscience Patient-derived Xenograft (PDX) Models Introduction
11.1.4 Crown Bioscience Revenue in Patient-derived Xenograft (PDX) Models Business (2020-2025)
11.1.5 Crown Bioscience Recent Development
11.2 Champions Oncology
11.2.1 Champions Oncology Company Details
11.2.2 Champions Oncology Business Overview
11.2.3 Champions Oncology Patient-derived Xenograft (PDX) Models Introduction
11.2.4 Champions Oncology Revenue in Patient-derived Xenograft (PDX) Models Business (2020-2025)
11.2.5 Champions Oncology Recent Development
11.3 Wuxi Apptec
11.3.1 Wuxi Apptec Company Details
11.3.2 Wuxi Apptec Business Overview
11.3.3 Wuxi Apptec Patient-derived Xenograft (PDX) Models Introduction
11.3.4 Wuxi Apptec Revenue in Patient-derived Xenograft (PDX) Models Business (2020-2025)
11.3.5 Wuxi Apptec Recent Development
11.4 The Jackson Laboratory
11.4.1 The Jackson Laboratory Company Details
11.4.2 The Jackson Laboratory Business Overview
11.4.3 The Jackson Laboratory Patient-derived Xenograft (PDX) Models Introduction
11.4.4 The Jackson Laboratory Revenue in Patient-derived Xenograft (PDX) Models Business (2020-2025)
11.4.5 The Jackson Laboratory Recent Development
11.5 EPO Berlin-Buch
11.5.1 EPO Berlin-Buch Company Details
11.5.2 EPO Berlin-Buch Business Overview
11.5.3 EPO Berlin-Buch Patient-derived Xenograft (PDX) Models Introduction
11.5.4 EPO Berlin-Buch Revenue in Patient-derived Xenograft (PDX) Models Business (2020-2025)
11.5.5 EPO Berlin-Buch Recent Development
11.6 Oncodesign
11.6.1 Oncodesign Company Details
11.6.2 Oncodesign Business Overview
11.6.3 Oncodesign Patient-derived Xenograft (PDX) Models Introduction
11.6.4 Oncodesign Revenue in Patient-derived Xenograft (PDX) Models Business (2020-2025)
11.6.5 Oncodesign Recent Development
11.7 Xentech
11.7.1 Xentech Company Details
11.7.2 Xentech Business Overview
11.7.3 Xentech Patient-derived Xenograft (PDX) Models Introduction
11.7.4 Xentech Revenue in Patient-derived Xenograft (PDX) Models Business (2020-2025)
11.7.5 Xentech Recent Development
11.8 Envigo
11.8.1 Envigo Company Details
11.8.2 Envigo Business Overview
11.8.3 Envigo Patient-derived Xenograft (PDX) Models Introduction
11.8.4 Envigo Revenue in Patient-derived Xenograft (PDX) Models Business (2020-2025)
11.8.5 Envigo Recent Development
11.9 Charles River Laboratories
11.9.1 Charles River Laboratories Company Details
11.9.2 Charles River Laboratories Business Overview
11.9.3 Charles River Laboratories Patient-derived Xenograft (PDX) Models Introduction
11.9.4 Charles River Laboratories Revenue in Patient-derived Xenograft (PDX) Models Business (2020-2025)
11.9.5 Charles River Laboratories Recent Development
11.10 Pharmatest Services
11.10.1 Pharmatest Services Company Details
11.10.2 Pharmatest Services Business Overview
11.10.3 Pharmatest Services Patient-derived Xenograft (PDX) Models Introduction
11.10.4 Pharmatest Services Revenue in Patient-derived Xenograft (PDX) Models Business (2020-2025)
11.10.5 Pharmatest Services Recent Development
11.11 Urosphere
11.11.1 Urosphere Company Details
11.11.2 Urosphere Business Overview
11.11.3 Urosphere Patient-derived Xenograft (PDX) Models Introduction
11.11.4 Urosphere Revenue in Patient-derived Xenograft (PDX) Models Business (2020-2025)
11.11.5 Urosphere Recent Development
11.12 MEDICILON
11.12.1 MEDICILON Company Details
11.12.2 MEDICILON Business Overview
11.12.3 MEDICILON Patient-derived Xenograft (PDX) Models Introduction
11.12.4 MEDICILON Revenue in Patient-derived Xenograft (PDX) Models Business (2020-2025)
11.12.5 MEDICILON Recent Development
11.13 Horizon Discovery
11.13.1 Horizon Discovery Company Details
11.13.2 Horizon Discovery Business Overview
11.13.3 Horizon Discovery Patient-derived Xenograft (PDX) Models Introduction
11.13.4 Horizon Discovery Revenue in Patient-derived Xenograft (PDX) Models Business (2020-2025)
11.13.5 Horizon Discovery Recent Development
11.14 Shanghai Model Organisms Center
11.14.1 Shanghai Model Organisms Center Company Details
11.14.2 Shanghai Model Organisms Center Business Overview
11.14.3 Shanghai Model Organisms Center Patient-derived Xenograft (PDX) Models Introduction
11.14.4 Shanghai Model Organisms Center Revenue in Patient-derived Xenograft (PDX) Models Business (2020-2025)
11.14.5 Shanghai Model Organisms Center Recent Development
11.15 GemPharmatech
11.15.1 GemPharmatech Company Details
11.15.2 GemPharmatech Business Overview
11.15.3 GemPharmatech Patient-derived Xenograft (PDX) Models Introduction
11.15.4 GemPharmatech Revenue in Patient-derived Xenograft (PDX) Models Business (2020-2025)
11.15.5 GemPharmatech Recent Development
11.16 LIDE Biotech
11.16.1 LIDE Biotech Company Details
11.16.2 LIDE Biotech Business Overview
11.16.3 LIDE Biotech Patient-derived Xenograft (PDX) Models Introduction
11.16.4 LIDE Biotech Revenue in Patient-derived Xenograft (PDX) Models Business (2020-2025)
11.16.5 LIDE Biotech Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
Crown Bioscience
Champions Oncology
Wuxi Apptec
The Jackson Laboratory
EPO Berlin-Buch
Oncodesign
Xentech
Envigo
Charles River Laboratories
Pharmatest Services
Urosphere
MEDICILON
Horizon Discovery
Shanghai Model Organisms Center
GemPharmatech
LIDE Biotech
听
听
*If Applicable.
